Assignee: Wyeth

Location: Madison, NJ
No. of patents: 755

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8168672	Thioamide derivatives as progesterone receptor modulators Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies. ...	05/01/2012
8163729	Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided...	04/24/2012
8158642	Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su...	04/17/2012
8088905	Nucleic acids encoding antibodies against PD-1 This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions ...	01/03/2012
8029561	Drug combination useful for prevention of restenosis The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent su...	10/04/2011
8007737	Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of bioc...	08/30/2011
7973044	Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su...	07/05/2011
7968547	Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su...	06/28/2011
7569564	Cyclothiocarbamate derivatives as progesterone receptor modulators Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have ...	08/04/2009
7566791	Substituted 3-carbonyl--indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives of formula I are provided: wherein: R1, R2, R3, R4 and R5 are as defined herein wh...	07/28/2009
7566776	Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the poly...	07/28/2009
7563931	Process for preparation of phenethylamine derivatives A process for the preparation of a compound of formula I, wherein R1 and R2 are ortho or para substituents, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6...	07/21/2009
7563905	Triazole derivatives and method of using the same to treat HIV infections The present invention is directed to compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl and het...	07/21/2009
7563813	Iminothiazolidinone derivatives as SFRP-1 antagonists Compounds of Formula 1, or pharmaceutically acceptable salts thereof, are provided: which are inhibitors of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat...	07/21/2009
7563796	Diphenylimidazopyrimidines as inhibitors of β-secretase The present invention provides an amino-imidazolone compound of formula I Also provided are compositions and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles...	07/21/2009
7563793	Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents This invention provides estrogen receptor modulators having the structure: wherein R1 to R7, R9, R10, X, Y, and Z are as defined in the specification; or a pharmaceutically accept...	07/21/2009
7560470	Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. ...	07/14/2009
7560457	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders The present invention provides compounds of the following structure, wherein R1, R2, R4, R4′, R6, R7, and R15 are defined above: These compounds a...	07/14/2009
7560441	Modified and stabilized GDF propeptides and uses thereof Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in w...	07/14/2009
7557237	Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile A process for making a compound of formula I and intermediate compounds thereof, wherein R1 is CN, F or Cl; R2 is H or Br; and R3 and R4 are each independently H or F. The compoun...	07/07/2009
7557135	Inhibitors of cytosolic phospholipase A This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes...	07/07/2009
7557098	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. ...	07/07/2009
7556938	Nucleic acids encoding potassium channel interactors The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, reco...	07/07/2009
7555415	Methods for the design of estrogen receptor ligands Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed. ...	06/30/2009
7553967	1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections The present invention is directed to compound of formula (A): wherein R1 is selected from (a) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl, or (b) CN and —C(NR10...	06/30/2009
7553873	Glutamate aggrecanase inhibitors The present invention relates to modulators of metalloproteinase activity. ...	06/30/2009
7553843	Process for the preparation of purified crystalline CCI-779 The present invention provides purified crystalline CCI-779 and processes for preparing the same. ...	06/30/2009
7553498	Pantoprazole multiparticulate formulations A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of ...	06/30/2009
7550485	Substituted N-heterocycle derivatives and methods of their use The present invention is directed to substituted N-heterocycle derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms...	06/23/2009
7550153	Pantoprazole multiparticulate formulations Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub...	06/23/2009
7547717	Ion channel modulators The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and...	06/16/2009
7544370	Pantoprazole multiparticulate formulations Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a distintegrant; a su...	06/09/2009
7541370	1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. ...	06/02/2009
7541154	GASP1: a follistatin domain containing protein The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disor...	06/02/2009
7538215	Compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su...	05/26/2009
7538113	4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists. ...	05/26/2009
7537766	inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof The present invention is directed to novel Neisseria meningitidis lipo-oligosaccharide inner core molecules, conjugates thereof and immunogenic compositions thereof. In particular embodiments, the invention relates to multivalent immunogenic compositions comp...	05/26/2009
7534801	Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor. ...	05/19/2009
7534766	Glucuronide metabolites and epimers thereof of tigecycline A glucuronide metabolite of tigecycline, and its corresponding epimer, have been identified in humans treated with tigecycline. Mass spectral data have been used to identify these structures. ...	05/19/2009
7531564	Substituted benzoxazoles as estrogenic agents This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in t...	05/12/2009

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Wyeth